We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.
With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy.
Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy.
Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
Company Growth (employees)
Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, US
Key People at Ionis Pharmaceuticals
Stanley Crooke
CEO
Lynne Parshall
COO / CFO
Elizabeth Hougen
Chief Accounting Officer
C. Frank Bennett
Senior Vice President of Research
Sarah Boyce
CBO
Steve Hughes
Chief Clinical Development Officer
Brett P. Monia
Senior Vice President of Antisense Drug Discovery
Ionis Pharmaceuticals Office Locations
Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, US (HQ)
2855 Gazelle Ct
Ionis Pharmaceuticals Data and Metrics
Ionis Pharmaceuticals Financial Metrics
Ionis Pharmaceuticals's revenue was reported to be $110.3 m in Q1, 2017
USD
Revenue (Q1, 2017) | 110.3 m |
Net income (Q1, 2017) | 3.5 m |
EBIT (Q1, 2017) | 14 m |
Market capitalization (22-Sep-2017) | 6.4 b |
Closing share price (22-Sep-2017) | 51.8 |
Cash (31-Mar-2017) | 114.2 m |
Ionis Pharmaceuticals's current market capitalization is $6.4 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 147.3 m | 214.2 m | 283.7 m | 346.6 m |
Revenue growth, % | 45% | 32% | 22% | |
General and administrative expense | 48.6 m | |||
Operating expense total | 48.6 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 57.1 m | 44.1 m | 62.6 m | 120.4 m | 49.1 m | 36.9 m | 38.5 m | 110.9 m | 110.3 m |
General and administrative expense | 4.5 m | 4.5 m | 7.5 m | 7.8 m | 8.8 m | 10.6 m | 9.8 m | 10.2 m | 13.7 m |
Operating expense total | 4.5 m | 4.5 m | 7.5 m | 7.8 m | 8.8 m | 10.6 m | 9.8 m | 10.2 m | 13.7 m |
EBIT | (6.7 m) | (21.5 m) | (9.3 m) | 44.6 m | (48.1 m) | (54.7 m) | (48.9 m) | 16.1 m | 14 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 160 m | 143 m | 128.8 m | 84.7 m |
Accounts Receivable | 51.1 m | |||
Inventories | 8 m | 6.3 m | 6.9 m | 7.5 m |
Current Assets | 735.5 m | 836.6 m | 837 m | 797.9 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 94.1 m | 73.2 m | 148.3 m | 119.5 m | 126.6 m | 93.3 m | 112.5 m | 84.3 m | 114.2 m |
Inventories | 7.8 m | 7.1 m | 6.8 m | 6.8 m | 6.6 m | 6.5 m | 7.7 m | 9.3 m | 6.8 m |
Current Assets | 705.8 m | 681.2 m | 835.4 m | 855.5 m | 868.3 m | 763.9 m | 698 m | 730.3 m | 962.4 m |
PP&E | 86.3 m | 88.1 m | 89 m | 89.7 m | 89.2 m | 90.4 m | 90.6 m | 91 m | 95.4 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (60.6 m) | (39 m) | (88.3 m) | (86.6 m) |
Depreciation and Amortization | 6.6 m | 6.4 m | 7 m | 7.5 m |
Inventories | (1.9 m) | 1.7 m | (609 k) | (590 k) |
Accounts Payable | 66 k | 4.8 m | 9.2 m | (10.7 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (12.1 m) | (26.7 m) | (16.7 m) | 35.6 m | (35.8 m) | (62.9 m) | (56.9 m) | 7.4 m | 3.5 m |
Inventories | 7.8 m | 7.1 m | 6.8 m | 6.8 m | 6.6 m | 6.5 m | 7.7 m | 9.3 m | 6.8 m |
Accounts Payable | 13.5 m | 15.6 m | 16.5 m | 11 m | 19.3 m | 19.5 m | 17.6 m | 15.7 m | 23.2 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 253.6 k |
Financial Leverage | 5.4 x |
Ionis Pharmaceuticals Market Value History
Market Position of Ionis Pharmaceuticals
Traffic Overview of Ionis Pharmaceuticals
Ionis Pharmaceuticals Online and Social Media Presence
Ionis Pharmaceuticals News and Updates
December 31, 2016
Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval
Spinraza, a “life-changing” drug for spinal muscular atrophy, will cost as much as $750,000 for the first year of treatment and $375,000 annually after that.
August 01, 2016
Stocks turn lower as oil prices continue to skid
U.S. stocks are slipping Monday afternoon as the price of oil continues to dive and energy companies take large losses. The strong dollar is again rippling through the market, pushing oil prices lower and pressuring energy and mining stocks. U.S. crude reached its lowest price in almost four mon…
August 01, 2016
Wall St. Moves Higher, Though Energy Stocks Keep Sliding
Tesla Motors agreed to buy the solar panel maker SolarCity for $2.6 billion in stock in a merger aimed at creating a one-stop shop for cleaner energy.
July 19, 2016
BRIEF-Ionis Pharmaceuticals licenses oral antisense drug to Janssen
* Ionis Pharmaceuticals licenses first oral antisense drug
acting locally in the GI tract to Janssen